Goldman Says "Good Opportunity To Buy Dip" In Obesity Drug Stocks

Novo Nordisk shares in Europe are showing signs of recovery after a significant downturn. Goldman Sachs analyst Faris Mourad recommends buying the dip in obesity drug stocks. He believes the obesity drugs narrative is gaining momentum despite lagging returns compared to the S&P 500. Mourad highlights the potential of emerging players and increasing competition in the obesity drug market. He notes large pharmaceutical companies are actively acquiring and licensing new obesity treatments. Goldman Sachs also identified industries potentially at risk from the rise of obesity drugs, such as those related to unhealthy lifestyles. 2026 is seen as a key year with the launch of new oral obesity drugs like Novo Nordisk's Wegovy pill. Analysts anticipate sales estimates for these drugs to surpass company consensus in the coming years. The market has been underestimating the revenue potential of oral Wegovy, according to the research. Despite recent challenges and price cuts, the long-term outlook for obesity drugs appears promising.